Efficacy 2 Part Study of Identification of Keloid Biomarkers and Effect of QAX576 on Keloid Recurrence

NCT00987545 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
3
Enrollment
INDUSTRY
Sponsor class

Stopped Negative pharmacodynamics due to lack of Interleukin-13 signature in biomarker data from Part I of the study.

Conditions

Interventions

Sponsor

Novartis Pharmaceuticals

Collaborators